PHARMACY

Rite Aid posts $118.1 million profit for fiscal year 2013

BY Alaric DeArment

CAMP HILL, Pa. — Rite Aid’s profits grew in fourth quarter and fiscal year 2013 amid stronger front-end sales and prescription count, the retail pharmacy chain said Thursday.

The company reported a $123.1 million profit for the fourth quarter and a $118.1 million profit for the fiscal year, compared with respective losses of $161.3 million and $368.6 million during the same period last year. In third quarter 2013, the company reported a profit of nearly $62 million, its first in five years, which together with the fourth quarter’s results helped deliver the company’s first profitable fiscal year since 2007.

Behind the results was a combination of stronger sales in Wellness-format stores, retention of most patients who switched to Rite Aid during the dispute between Walgreens and pharmacy benefit manager Express Scripts – which ended last year, but forced millions of Walgreens customers to fill their prescriptions at other retailers – the Wellness+ loyalty card program and increased use of generics.

"Together, we are successfully transforming Rite Aid into a true neighborhood destination for health and wellness," president, chairman and CEO John Standley said in a conference call with analysts to discuss the results.

Of the chain’s 4,623 stores, 797 are Wellness stores, and CFO and chief administrative officer Frank Vitrano said during the call that the format’s front-end comps exceed those of non-Wellness stores by more than 3%. A major factor is the Wellness Ambassadors, specially trained staff members who walk the aisles of the stores with iPads and provide information on health and wellness products and pharmacy services, acting as a "bridge" between the front end and pharmacy. The company reported that it had 1,300 Wellness Ambassadors trained at the end of the quarter. "Simply put, our Wellness Ambassadors can help grow our business by providing strong customer relationships," COO Ken Martindale said during the call.

The company plans to remodel 400 more stores in fiscal year 2014, the "vast majority" of which will be remodeled according to the updated "Genuine Well-Being" format, similar to the updated Wellness store in Lemoyne, Pa., featured in a recent video on Drug Store News’ website. For this purpose, $175 million of the $400 million Rite Aid plans to invest in the year has been set aside.

In addition to the lift from Wellness stores, the company has seen a 3% benefit in pharmacy comps, thanks in large part to the retention of customers from the Walgreens-ESI dispute. Vitrano said the company had retained 75-80% of the scripts it gained from the dispute. While the company expects that it may continue to lose some of those customers, it nevertheless expects to retain most of them.

A major factor in that retention has been the Wellness+ loyalty card program. To date, the program has nearly 25.2 million active members, defined as those who have used it at least twice over the past 26 weeks. Members accounted for 79% of front-end sales and 68% of prescriptions filled, Martindale said, adding that Gold and Silver members have continued to increase in number, and more than 50% of those customers shop at Rite Aid stores every week.

Another factor in the company’s growth has been patients with multiple chronic health conditions, also known as poly-chronic patients, who tend to be elderly. Standley said a "big chunk" of the chain’s scripts and "virtually all" of its best customers were poly-chronic patients.

Vaccinations also beat the company’s expectations, as it performed 2.4 million flu vaccinations and 400,000 vaccinations for conditions like pneumonia, shingles and whooping cough. The company had expected to perform 2 million flu vaccinations during the year.

Sales for the fourth quarter were $6.5 billion, compared to $7.1 billion in fourth quarter 2012. Sales for fiscal year 2013 were $25.4 billion, compared to $26.1 billion in fiscal year 2012.

Same-store sales for the quarter decreased 2%, including a 0.3% increase in front-end same-store sales and a 3.1% decrease in the pharmacy. For the fiscal year, same-store sales decreased 0.3%, including a 1.4% increase in front-end same-store sales and a 1% decrease in pharmacy same-store sales. Same-store prescription count increased 3% for the quarter and 3.4% for the fiscal year.

The decrease in total-store and same-store sales was due to one less week in fiscal year 2013 and also because of greater dispensing of generic drugs. The company noted that while the large-scale shift to generics – also known as the generic wave – results in lower sales, it also helps to drive gross profit.

Wall Street responded with optimism to the results. "Importantly, the underlying business, excluding the generic benefit and the Walgreen windfall, appears quite healthy," Guggenheim Partners analyst John Heinbockel wrote in a note to investors. Rite Aid’s stock was trading at $2.08 per share in late-morning trading Thursday, up from $1.98 at the start of the day.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

CVS Caremark releases annual insights report on drug spend

BY Antoinette Alexander

WOONSOCKET, R.I. — The increased availability of generics combined with CVS Caremark’s generic dispensing rate of 77.4% helped reduce spending on traditional medications by 3.6% for the company’s commercial clients, according to its newly released annual insights report, which reviews drug trend and highlights key issues in pharmacy care.

CVS Caremark’s GDR is the result of two elements.  First, 2012 marked a high point in the flood of generic launches, with the estimated market value of brands that lost their patents in 2012 exceeding $35 billion. 

Second, CVS Caremark worked closely with PBM clients to maximize the cost-saving opportunities posed by generics as broadly as possible, using strategies such as formulary management and step therapy plan designs to encourage the use of cost-effective generic drugs. In fact, the retailer stated that 70% of its plan sponsors use generic step therapy or are considering implementing it in the near future.

While spending for traditional medications decreased, spending on specialty medications grew by 18.1% for commercial clients, becoming the main driver of overall drug trend of 0.3%. Specialty drugs treat more complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer. Overall, specialty drugs now represent nearly 20% of total drug spend among CVS Caremark clients, growing by three percentage points and representing the largest increase in the past six years.

"As the generic wave begins to subside in the coming years, the impact of specialty pharmacy on client spend will only increase," stated Jon Roberts, president of CVS Caremark’s PBM business. "We know that specialty pharmacy trend is driven by the same forces – utilization, price and drug mix – a trend for more traditional drugs. Although biogenerics are not yet a factor in helping to manage costs, CVS Caremark is still able to provide a variety of solutions to help our clients effectively manage their specialty pharmacy spend while continuing to ensure access to these medications for the patients who need them."

In addition to tracking drug trends, CVS Caremark analyzed the impact of improved medication adherence for its PBM clients. "In 2012, CVS Caremark’s commercial clients benefited from cost savings of more than $643 million on their overall healthcare spend as the result of improved medication adherence for chronic conditions," added Roberts.

The adherence cost savings were calculated using the company’s Pharmacy Care Economic Model, which enables CVS Caremark to calculate the financial value of improved pharmacy care by taking a holistic approach to reviewing adherence, gaps in care and use of generic alternatives, the company stated. CVS Caremark’s pharmacy care programs such as Pharmacy Advisor are succeeding in moving a significant portion of PBM members to optimal levels of medication adherence, the company noted.  The savings calculated using the PCEM are due to medical cost avoidance, closing gaps in care, drug cost savings and productivity loss avoidance.


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Maryland state legislature shelves biosimilars legislation

BY Alaric DeArment

WASHINGTON — Legislation designed to limit the use of biosimilars has met defeat in Maryland.

The legislation, which would limit the ability of pharmacists to substitute follow-on biologics for branded biotech drugs, failed to go forward in the state legislature. Last month, Virginia Gov. Bob McDonnell signed a similar bill into law, but the bill contained a sunset clause that will cause it to expire after five years, while the Florida Senate Committee on Health Policy passed a similar bill, also with a sunset clause. So far, North Dakota is the only state to pass such a bill intact.

"We applaud the Maryland state legislature for making this wise decision," Generic Pharmaceutical Association president and CEO Ralph Neas said. "After hours of testimony, members of the House were convinced that now is not the time to take action."

Similar legislation has also met rejection in the state legislatures of Arizona, Mississippi and Washington.


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?